We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Repligen (RGEN - Free Report) . Shares have added about 27.7% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Repligen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Repligen reported second-quarter 2026 adjusted earnings per share of 54 cents, which beat the Zacks Consensus Estimate of 45 cents. In the year-ago quarter, the company reported adjusted earnings of 37 cents per share.
Total revenues in the second quarter were $204.1 million, up 12% year over year on a reported basis. Excluding the impact of acquisitions and currency exchange, revenues rose 13% organically. Revenues also beat the Zacks Consensus Estimate of $202 million.
Quarter in Detail
The company’s top line comprises product revenues and negligible royalties and other revenues.
Product revenues were $204.1 million, up almost 12% from the year-ago level. Royalty and other revenues amounted to $0.04 million, up around 16% year over year.
Repligen records revenues from its business franchisees that can be categorized as filtration, chromatography, proteins and process analytics.
Total orders remained strong, like some previous quarters, with all the franchises witnessing year-over-year growth during the second quarter. Filtration revenues grew slightly on a reported basis in the quarter, driven by consumable demand, including fluid management and flat sheet cassettes.
Chromatography revenues increased in low double digits during the quarter, driven by growth in OPUS columns.
Proteins grew 50% year over year. Biopharma revenues also grew during the second quarter, driven by growth from emerging biotech. CDMO revenues also witnessed strong growth year over year during the quarter.
In the reported quarter, Process Analytics revenues grew more than 30% year over year, led by strength across consumables, services and capital equipment.
Costs, Margins & Cash Position
Adjusted gross margin was 53.9%, reflecting an increase of 280 basis points year over year.
Adjusted operating income totaled $34 million, reflecting an increase of 55% year over year.
Adjusted operating margin was 16.7% in the second quarter, higher than 12% in the year-ago quarter.
As of June 30, 2026, Repligen had cash and cash equivalents worth $810 million compared with $785 million as of March 31, 2026.
2026 Guidance
Repligen increased its full-year 2026 revenue guidance as well as EPS outlook.
The company now expects total revenues in the range of $813-$835 million in 2026, compared with the previous expectation of $803-$833 million.
Importantly, Repligen now expects reported revenue growth of 10-13% and organic revenue growth of 10.5%-13.5% in 2026. Previously, the company expected reported as well as organic revenue growth of 9%-13%.
Adjusted EPS is now anticipated to be between $2.03 and $2.09 for full-year 2026, up from the previous expectation of $1.97 and $2.05.
Adjusted gross margin is expected to be between 53.7% and 54.2% for 2026, unchanged from the previous expectation.
Adjusted operating income is now expected in the range of $128-$134 million, up from the earlier expectation of $124-$132 million.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended upward during the past month.
VGM Scores
At this time, Repligen has a poor Growth Score of F, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock has a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. It comes with little surprise Repligen has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
It has been about a month since the last earnings report for Repligen (RGEN - Free Report) . Shares have added about 27.7% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Repligen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Repligen Beats Q2 Earnings Estimates, Raises 2026 View
Repligen reported second-quarter 2026 adjusted earnings per share of 54 cents, which beat the Zacks Consensus Estimate of 45 cents. In the year-ago quarter, the company reported adjusted earnings of 37 cents per share.
Total revenues in the second quarter were $204.1 million, up 12% year over year on a reported basis. Excluding the impact of acquisitions and currency exchange, revenues rose 13% organically. Revenues also beat the Zacks Consensus Estimate of $202 million.
Quarter in Detail
The company’s top line comprises product revenues and negligible royalties and other revenues.
Product revenues were $204.1 million, up almost 12% from the year-ago level. Royalty and other revenues amounted to $0.04 million, up around 16% year over year.
Repligen records revenues from its business franchisees that can be categorized as filtration, chromatography, proteins and process analytics.
Total orders remained strong, like some previous quarters, with all the franchises witnessing year-over-year growth during the second quarter. Filtration revenues grew slightly on a reported basis in the quarter, driven by consumable demand, including fluid management and flat sheet cassettes.
Chromatography revenues increased in low double digits during the quarter, driven by growth in OPUS columns.
Proteins grew 50% year over year. Biopharma revenues also grew during the second quarter, driven by growth from emerging biotech. CDMO revenues also witnessed strong growth year over year during the quarter.
In the reported quarter, Process Analytics revenues grew more than 30% year over year, led by strength across consumables, services and capital equipment.
Costs, Margins & Cash Position
Adjusted gross margin was 53.9%, reflecting an increase of 280 basis points year over year.
Adjusted operating income totaled $34 million, reflecting an increase of 55% year over year.
Adjusted operating margin was 16.7% in the second quarter, higher than 12% in the year-ago quarter.
As of June 30, 2026, Repligen had cash and cash equivalents worth $810 million compared with $785 million as of March 31, 2026.
2026 Guidance
Repligen increased its full-year 2026 revenue guidance as well as EPS outlook.
The company now expects total revenues in the range of $813-$835 million in 2026, compared with the previous expectation of $803-$833 million.
Importantly, Repligen now expects reported revenue growth of 10-13% and organic revenue growth of 10.5%-13.5% in 2026. Previously, the company expected reported as well as organic revenue growth of 9%-13%.
Adjusted EPS is now anticipated to be between $2.03 and $2.09 for full-year 2026, up from the previous expectation of $1.97 and $2.05.
Adjusted gross margin is expected to be between 53.7% and 54.2% for 2026, unchanged from the previous expectation.
Adjusted operating income is now expected in the range of $128-$134 million, up from the earlier expectation of $124-$132 million.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended upward during the past month.
VGM Scores
At this time, Repligen has a poor Growth Score of F, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock has a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. It comes with little surprise Repligen has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.